Evidence map›Paper›PMID 23250488›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2013

Translational control of inducible nitric oxide synthase by p38 MAPK in islet β-cells.

Yurika Nishiki, Adeola Adewola, Masayuki Hatanaka, Andrew T Templin, Bernhard Maier, Raghavendra G Mirmira

Registry-linked trialAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05594563 (TArgeting Type 1 Diabetes Using POLyamines), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05594563 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes

TypeinterventionalSponsorEmily K. SimsRan2023 to 2027Enrolled74ConditionsType 1 DiabetesArmsDFMO, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Distinct differences in the responses of the human pancreatic β-cell line EndoC-βH1 and human islets to proinflammatory cytokines.American journal of physiology. Regulatory, integrative and comparative physiology · 2015
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yurika NishikiDepartment of Pediatrics and the Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
Adeola Adewola
Masayuki Hatanaka
Andrew T Templin
Bernhard Maier
Raghavendra G Mirmira
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · US

Funding

Transcriptional Mechanisms Governing Beta Cell DifferentiationR01DK060581 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Raghavendra G Mirmira · 2002 to 2026
$8.5M
RESEARCH TRAINING PROGRAM IN DIABETES AND OBESITYT32DK064466 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Carmella Evans-Molina, RONALD C WEK · 2003 to 2026
$5.2M
NIDDK NIH HHS R01 DK060581NIDDK NIH HHS R01 DK60581NIDDK NIH HHS T32 DK064466
6 · The paper itself

Abstract

The MAPKs are transducers of extracellular signals such as proinflammatory cytokines. In islet β-cells, cytokines acutely activate expression of the Nos2 gene encoding inducible nitric oxide synthase (iNOS), which ultimately impairs insulin release. Because iNOS production can also be regulated posttranscriptionally, we asked whether MAPKs participate in posttranscriptional regulatory events in β-cells and primary islets in response to cytokine signaling. We show that cytokines acutely reduce cellular oxygen consumption rate and impair aconitase activity. Inhibition of iNOS with l-NMMA or inhibition of Nos2 mRNA translation with GC7 [an inhibitor of eukaryotic translation initiation factor 5A (eIF5A) activity] reversed these defects, as did inhibition of p38 MAPK by PD169316. Although inhibition of p38 had no effect on the nuclear translocation of nuclear factor κB or the abundance of Nos2 transcripts during the immediate period after cytokine exposure, its inhibition or knockdown resulted in significant reduction in iNOS protein, a finding suggestive of a permissive role for p38 in Nos2 translation. Polyribosomal profiling experiments using INS-1 β-cells revealed that Nos2 mRNA remained associated with polyribosomes in the setting of p38 inhibition, in a manner similar to that seen with blockade of translational elongation by cycloheximide. Consistent with a role in translational elongation, p38 activity is required in part for the activation of the translational factor eIF5A by promoting its hypusination. Our results suggest a novel signaling pathway in β-cells in which p38 MAPK promotes translation elongation of Nos2 mRNA via regulation of eIF5A hypusination.

Indexed as

Aconitate HydrataseAnimalsCell LineCycloheximideCytokinesEnzyme InhibitorsEukaryotic Translation Initiation Factor 5AGuanineHumansImidazolesInsulinInsulin-Secreting CellsInsulin SecretionMiceMitogen-Activated Protein Kinase 14NF-kappa B2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazoleAconitate HydrataseCycloheximideCytokinesEnzyme InhibitorsEukaryotic Translation Initiation Factor 5AGuanineImidazolesInsulinMitogen-Activated Protein Kinase 14N(1)-guanyl-1,7-diaminoheptaneNF-kappa BNitric Oxide Synthase Type IIomega-N-MethylargininePeptide Initiation FactorsProtein Synthesis InhibitorsRNA-Binding ProteinsRNA, Small Interfering

Identifiers

PMID23250488
PMCPMC3683810
OpenAlexW2012669126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.